Effect of AR antagonist combined with PARP1 inhibitor on sporadic triple-negative breast cancer bearing AR expression and methylation-mediated BRCA1 dysfunction

Effect of AR antagonist combined with PARP1 inhibitor on sporadic triple-negative breast cancer bearing AR expression and methylation-mediated BRCA1 dysfunction

Triple-negative breast cancer (TNBC) patients usually present worse clinical outcomes due to their high heterogeneity. The purpose of our study is to investigate the prognostic role of AR and BRCA1 expression in sporadic TNBC patients, and effect of AR blockade and PARP1 inhibitor for TNBC patients...

Full description

Bibliographic Details
Main Authors: Meixiang Sang, Lingjiao Meng, Cuicui Ma, Sihua Liu, Meijie Sang, Sheng Chang, Fei Liu, Yishui Lian, Cuizhi Geng
Format: Article
Language:English
Published: Elsevier 2019-03-01
Series:Biomedicine & Pharmacotherapy
Subjects:
Triple-negative breast cancer
Androgen receptor
BRCA1
Enzalutamide
Olaparib
Online Access:http://www.sciencedirect.com/science/article/pii/S0753332218372640

Internet

http://www.sciencedirect.com/science/article/pii/S0753332218372640

Similar Items